Navigation Links
Chemotherapy Superior to New Drug for Early Breast Cancer
Date:5/13/2009

Standard treatment prolonged survival in older women, study finds ,,,,

WEDNESDAY, May 13 (HealthDay News) -- Older women with early-stage breast cancer do better after standard chemotherapy than they do with the oral drug capecitabine (Xeloda), a new study finds.

"After three years, 85 percent of people who received chemotherapy were doing well, and 68 percent of people who received capecitabine were doing well," said lead researcher Dr. Hyman Muss, a professor of medicine at the University of North Carolina at Chapel Hill.

"In this trial, we had hoped that it [capecitabine] would be as good as standard therapy, so we would have a pill treatment with less side effects, but it turned out it wasn't as good," Muss said.

The report is published in the May 14 issue of the New England Journal of Medicine.

Because it has fewer side effects, capecitabine has been approved by the U.S. Food and Drug Administration for use in patients with advanced breast and colon cancer. Used in this context, it improves quality of life and may extend life for several months, the researchers said.

For the study, Muss and colleagues randomly assigned 600 women aged 65 and older with early-stage breast cancer to standard treatment with a combination of chemotherapy drugs or capecitabine.

Women taking capecitabine were roughly twice as likely to have a relapse of their cancer or die, the researchers found. Three years after treatment, 85 percent of women who received standard chemotherapy were alive and cancer-free compared with 68 percent of the women who received capecitabine, the team found.

The greatest benefit of chemotherapy was among the minority of women with hormone receptor-negative breast cancer, Muss said.

However, in women whose cancer is hormone receptor-positive, "we showed that standard therapy and capecitabine were pretty similar," Muss said. "It would be reasonable for these women to select capecitabine over standard chemotherapy, but my bias would still be to pick the standard right now."

Other studies with women younger than 70 have also found standard chemotherapy provided better outcomes than a single drug, the researchers noted.

Dr. Nancy Davidson, director of the University of Pittsburgh Cancer Institute, thinks that the results of this study confirm the benefit of chemotherapy for treating women with early-stage breast cancer.

"This is a critical trial for two reasons," Davidson said. "It demonstrates that properly selected older women, who comprise the vast majority of patients with breast cancer, can benefit from state of the art chemotherapy just as younger women do. Thus, age alone should not be a reason to withhold chemotherapy," she said.

"It also demonstrates, yet again, that multi-agent chemotherapy gives better results than single agent chemotherapy for early breast cancer," Davidson said. "This trial does not say that capecitabine is an inactive drug -- rather its routine use should be limited to women with advanced breast cancer where it is used quite successfully as a way to minimize symptoms of disease. It is also very useful in other cancers like colon cancer."

Barbara A. Brenner, executive director of Breast Cancer Action, thinks most women like those in the study should opt for standard chemotherapy.

"The premise is always, if there is something new, let's do it, it will be better, and this actually shows that this is not the case," Brenner said.

Brenner doesn't think women should choose capecitabine even though its benefit is close to chemotherapy in some women. "Close, but not close enough," she said.

In selecting a breast cancer treatment, women should ask their doctor about their chance of relapse, Brenner stressed. "Make your best informed decision," she said.

More information

For more on breast cancer, visit the American Cancer Society.



SOURCES: Hyman Muss, M.D., professor, medicine, University of North Carolina at Chapel Hill; Barbara A. Brenner, J.D., executive director, Breast Cancer Action, San Francisco; Nancy Davidson, M.D., director, University of Pittsburgh Cancer Institute; May 14, 2009, New England Journal of Medicine


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa
2. 3-drug chemotherapy combination increases organ preservation in patients with larynx cancer
3. Scientists trial device to treat chemotherapy-related nausea
4. Lung Cancer Microscopic Appearance Affects Response to Chemotherapy
5. Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy
6. How chemotherapy drugs block blood vessel growth, slow cancer spread
7. UNC study supports role of circadian clock in response to chemotherapy
8. Gene Governs Response to Leukemia Chemotherapy
9. Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
10. Oncologists Rank Aloxis Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
11. Studies show novel device may enhance chemotherapy treatment in brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Chemotherapy Superior to New Drug for Early Breast Cancer
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology: